作者:Rainer Gewald、Christian Grunwald、Ute Egerland
DOI:10.1016/j.bmcl.2013.05.099
日期:2013.8
Expanding on HTS hit 4 afforded a series of [1,3,5]triazine derivatives as novel PDE4 inhibitors. The SAR development and optimization process with the emphasis on ligand efficiency and physicochemical properties led to the discovery of compound 44 as a potent, selective and orally active PDE4 inhibitor.
在HTS命中4上的扩展提供了一系列[1,3,5]三嗪衍生物作为新型PDE4抑制剂。SAR的发展和优化过程着重于配体效率和理化性质,导致发现了化合物44作为有效,选择性和口服活性的PDE4抑制剂。